Objective.To establish a flow cytometric internal standard method for counting platelet-derived microparti-cles(PMPs)and to study its clinical significance. Methods. PMPs suspension(platelet poor plasma,PPP) was extra...Objective.To establish a flow cytometric internal standard method for counting platelet-derived microparti-cles(PMPs)and to study its clinical significance. Methods. PMPs suspension(platelet poor plasma,PPP) was extracted by gradual centrifugation. According to the size of PMPs,3 μm and 0.8μm latex beads were used as internal standards for the quantitation. PMPs were counted by adjusting flow cytometric discrimination and voltage of forward scatter and side scatter. Results. In 30 healthy donors,the average concentration of resting PMPs was(1.2×105±5.7×104 )/ml and that of activated PMPs was(1.6×106±9.1×105)/ml. Compared with healthy donors,PMPs mean value was significantly higher(P< 0.001)in 18 patients with coronary artery disease,12 with acute cerebral infraction and 23 with chronic renal failure[the average PMPs concentration,( 6.1×105±2.5×105 )/ml, ( 6.8×105±3.4×105)/ml and(5.9×105±3.1×105)/ml respectively]. However,no significant difference in PMPs concentration was observed in 25 patients with acute leukemia and severe thrombocytopenia during the aplastic phase after chemotherapy [1.3×105±6.1×104)/ml,(P >0.05)] .Conclusions. PMPs is a useful indicator in monitoring platelet activation,and plays an important role in thrombotic disease. By flow cytometric internal standard method,PMPs can be counted rapidly and accurately,which may be very helpful in interlaboratory comparative studies.展开更多
AIM To evaluate platelet activation markers in psoriasis patients, compared to controls, and investigate their association with the inflammatory burden of psoriasis.METHODS Forty psoriatic patients without cardiovascu...AIM To evaluate platelet activation markers in psoriasis patients, compared to controls, and investigate their association with the inflammatory burden of psoriasis.METHODS Forty psoriatic patients without cardiovascular disease,and 12 healthy controls were subjected to measurement of baseline platelet CD62 P, CD63 and CD42 b expression, platelet-leukocyte complexes, i.e., platelet-monocyte complexes(PMC), platelet-neutrophil complexes(PNC) and platelet-lymphocyte complexes, and concentrations of platelet-derived microparticles(PMPs) using flow cytometry. Both larger-size(0.5-0.9 μm) and smallersize(< 0.5 μm) PMPs were determined. Serum interleukin(IL)-12 and IL-17 levels were also measured by enzyme-linked immunosorbent assay. The severity of psoriasis was evaluated by the Psoriasis Area Severity Index(PASI).RESULTS PMP concentrations were significantly higher in psoriasis patients than controls [mean±standard error of mean(SEM): 22±5/μL vs 11±6/μL; P=0.018), for both smaller-size(10±2/μL vs 4±2/μL; P=0.033) and larger-size(12±3/μL vs 6±4/μL; P=0.014) PMPs. Platelet CD62 P, CD63 and CD42 b expression and circulating PMC and PNC were similar between the two groups. Lower circulating PLC were observed in psoriasis patients compared to controls(mean±SEM: 16%±3% vs 23%±6%; P=0.047). Larger-size PMPs were related with IL-12 levels(P<0.001) and smaller-size PMPs with both IL-12 and IL-17 levels(P<0.001). Total PMPs also correlated with IL-12(P<0.001). CD63 expression was positively correlated with both IL-12 and IL-17(P<0.05). Increased PASI score was associated with increased levels of larger-size PMPs(r=0.45; P=0.011) and increased CD63 expression(r=0.47; P<0.01).CONCLUSION PMPs, known to be predictive of cardiovascular outcomes, are increased in psoriasis patients, and associated with high inflammatory disease burden. Enhanced platelet activation may be the missing link leading to cardiovascular events in psoriatic patients.展开更多
Microparticles (MPs) are membrane vesicles released by platelets during activation or apoptosis. PMPs stimulate coagulation and cell adhesion to the vascular endothelium, both of which being important in the developme...Microparticles (MPs) are membrane vesicles released by platelets during activation or apoptosis. PMPs stimulate coagulation and cell adhesion to the vascular endothelium, both of which being important in the development of cancer progression. We investigated the correlation between microparticles and cancer advancement. The percentage of PMPs was measured by flow cytometry in 22 colorectal cancer patients and in 20 healthy subjects. The patients were divided into two groups according to the presence or lack of lymph node metastases. The percentage of PMPs was significantly higher in patients than in healthy subjects (p < 0.001). We observed a positive correlation between PMPs and the presence of lymph node metastases (r = 0.63, p < 0.003). This high correlation may suggest that PMPs are associated with lymph node involvement and cancer progression.展开更多
目的探讨替罗非班冠状动脉给药在急性ST段抬高型心肌梗死(STEMI)患者直接经皮冠状动脉介入治疗(PCI)中的临床疗效及对外周血内血小板微粒(PMPs)水平的影响。方法选取2012年7月至2013年12月被确诊为急性STEMI并接受PCI治疗的患者124例,...目的探讨替罗非班冠状动脉给药在急性ST段抬高型心肌梗死(STEMI)患者直接经皮冠状动脉介入治疗(PCI)中的临床疗效及对外周血内血小板微粒(PMPs)水平的影响。方法选取2012年7月至2013年12月被确诊为急性STEMI并接受PCI治疗的患者124例,按照随机数字法将入组患者分为替罗非班组(62例)和对照组(62例),对照组予以常规PCI治疗;替罗非班组行PCI联合应用替罗非班治疗。比较两组患者术前的临床基础资料特征,术后病变血管心肌梗死溶栓治疗(TIMI)3级血流、校正的TIMI血流计数帧数(CTFC)、心肌灌注(TMPG)3级水平、术后90 min ST段回落程度>50%发生率;磷酸肌酸激酶同工酶(CK-MB)峰值及峰值时间和心肌肌钙蛋白I(cTnI)峰值。术后的左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD);PCI手术前后两组患者外周血内PMPs水平变化;术后3个月内主要心脏不良事件(MACE)及出血事件发生率。结果术前两组患者基本临床资料比较,差异均无统计学意义(均p>0.05)。术后替罗非班组TIMI3级血流、TMP3级水平发生率和术后90 min ST段回落程度>50%发生率均高于对照组(P<0.05),校正TIMI帧数低于对照组(P<0.05);替罗非班组术后LVEF值明显高于对照组,LVEDD、LVESD值明显低于对照组(P<0.05);术前两组PMPs水平比较差异无统计学意义(P>0.05),术后两组PMPs水平均出现显著降低(P<0.05),替罗非班组PMPs水平显著低于对照组(P<0.05)。术后3个月内MACE发生率显著低于对照组(P<0.05),出血并发症发生率比较,差异无统计学意义(P>0.05)。结论在STEMI急诊PCI治疗患者中,替罗非班冠脉内给药可以明显改善术后心肌再灌注和近期心功能,降低外周血内PMPs水平和主要不良心血管事件发生率,并未增加出血事件发生率,临床应用安全有效。展开更多
Platelet microparticles(PMPs)are membrane particles derived from the platelet membrane that enter into the blood circulation.We sought to explore the therapeutic effects of Tao-Hong-Si-Wu Decoction(THSWD)on angiogenes...Platelet microparticles(PMPs)are membrane particles derived from the platelet membrane that enter into the blood circulation.We sought to explore the therapeutic effects of Tao-Hong-Si-Wu Decoction(THSWD)on angiogenesis in a rat model of cerebral ischaemia-reperfusion(I/R).The protective effect of THSWD on I/R rats was observed morphologically by immunohistochemical expression of VEGF and CD34,along with immunofluorescence results of co-expression of Brd U and v WF.Then,PMPs from different groups of rats were extracted,and cytokine array analysis was used to screen for angiogenesis associated proteins.The results showed that THSWD can promote the expression of VEGF,CD34,Brd U and v WF.Cytokine array analysis revealed the changes in the expression of 29 related angiogenic proteins in the total protein of PMPs,which involved the Notch signalling pathway.Compared with model group,the expression levels of NICD and Hes-1 in the THSWD group were significantly increased.In the context of I/R,the angiogenesis-related proteins of PMPs are different.THSWD may involve the promotion of activation of the Notch signalling pathway to achieve therapeutic effects on cerebral ischaemia.展开更多
文摘Objective.To establish a flow cytometric internal standard method for counting platelet-derived microparti-cles(PMPs)and to study its clinical significance. Methods. PMPs suspension(platelet poor plasma,PPP) was extracted by gradual centrifugation. According to the size of PMPs,3 μm and 0.8μm latex beads were used as internal standards for the quantitation. PMPs were counted by adjusting flow cytometric discrimination and voltage of forward scatter and side scatter. Results. In 30 healthy donors,the average concentration of resting PMPs was(1.2×105±5.7×104 )/ml and that of activated PMPs was(1.6×106±9.1×105)/ml. Compared with healthy donors,PMPs mean value was significantly higher(P< 0.001)in 18 patients with coronary artery disease,12 with acute cerebral infraction and 23 with chronic renal failure[the average PMPs concentration,( 6.1×105±2.5×105 )/ml, ( 6.8×105±3.4×105)/ml and(5.9×105±3.1×105)/ml respectively]. However,no significant difference in PMPs concentration was observed in 25 patients with acute leukemia and severe thrombocytopenia during the aplastic phase after chemotherapy [1.3×105±6.1×104)/ml,(P >0.05)] .Conclusions. PMPs is a useful indicator in monitoring platelet activation,and plays an important role in thrombotic disease. By flow cytometric internal standard method,PMPs can be counted rapidly and accurately,which may be very helpful in interlaboratory comparative studies.
文摘AIM To evaluate platelet activation markers in psoriasis patients, compared to controls, and investigate their association with the inflammatory burden of psoriasis.METHODS Forty psoriatic patients without cardiovascular disease,and 12 healthy controls were subjected to measurement of baseline platelet CD62 P, CD63 and CD42 b expression, platelet-leukocyte complexes, i.e., platelet-monocyte complexes(PMC), platelet-neutrophil complexes(PNC) and platelet-lymphocyte complexes, and concentrations of platelet-derived microparticles(PMPs) using flow cytometry. Both larger-size(0.5-0.9 μm) and smallersize(< 0.5 μm) PMPs were determined. Serum interleukin(IL)-12 and IL-17 levels were also measured by enzyme-linked immunosorbent assay. The severity of psoriasis was evaluated by the Psoriasis Area Severity Index(PASI).RESULTS PMP concentrations were significantly higher in psoriasis patients than controls [mean±standard error of mean(SEM): 22±5/μL vs 11±6/μL; P=0.018), for both smaller-size(10±2/μL vs 4±2/μL; P=0.033) and larger-size(12±3/μL vs 6±4/μL; P=0.014) PMPs. Platelet CD62 P, CD63 and CD42 b expression and circulating PMC and PNC were similar between the two groups. Lower circulating PLC were observed in psoriasis patients compared to controls(mean±SEM: 16%±3% vs 23%±6%; P=0.047). Larger-size PMPs were related with IL-12 levels(P<0.001) and smaller-size PMPs with both IL-12 and IL-17 levels(P<0.001). Total PMPs also correlated with IL-12(P<0.001). CD63 expression was positively correlated with both IL-12 and IL-17(P<0.05). Increased PASI score was associated with increased levels of larger-size PMPs(r=0.45; P=0.011) and increased CD63 expression(r=0.47; P<0.01).CONCLUSION PMPs, known to be predictive of cardiovascular outcomes, are increased in psoriasis patients, and associated with high inflammatory disease burden. Enhanced platelet activation may be the missing link leading to cardiovascular events in psoriatic patients.
文摘Microparticles (MPs) are membrane vesicles released by platelets during activation or apoptosis. PMPs stimulate coagulation and cell adhesion to the vascular endothelium, both of which being important in the development of cancer progression. We investigated the correlation between microparticles and cancer advancement. The percentage of PMPs was measured by flow cytometry in 22 colorectal cancer patients and in 20 healthy subjects. The patients were divided into two groups according to the presence or lack of lymph node metastases. The percentage of PMPs was significantly higher in patients than in healthy subjects (p < 0.001). We observed a positive correlation between PMPs and the presence of lymph node metastases (r = 0.63, p < 0.003). This high correlation may suggest that PMPs are associated with lymph node involvement and cancer progression.
文摘目的探讨替罗非班冠状动脉给药在急性ST段抬高型心肌梗死(STEMI)患者直接经皮冠状动脉介入治疗(PCI)中的临床疗效及对外周血内血小板微粒(PMPs)水平的影响。方法选取2012年7月至2013年12月被确诊为急性STEMI并接受PCI治疗的患者124例,按照随机数字法将入组患者分为替罗非班组(62例)和对照组(62例),对照组予以常规PCI治疗;替罗非班组行PCI联合应用替罗非班治疗。比较两组患者术前的临床基础资料特征,术后病变血管心肌梗死溶栓治疗(TIMI)3级血流、校正的TIMI血流计数帧数(CTFC)、心肌灌注(TMPG)3级水平、术后90 min ST段回落程度>50%发生率;磷酸肌酸激酶同工酶(CK-MB)峰值及峰值时间和心肌肌钙蛋白I(cTnI)峰值。术后的左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD);PCI手术前后两组患者外周血内PMPs水平变化;术后3个月内主要心脏不良事件(MACE)及出血事件发生率。结果术前两组患者基本临床资料比较,差异均无统计学意义(均p>0.05)。术后替罗非班组TIMI3级血流、TMP3级水平发生率和术后90 min ST段回落程度>50%发生率均高于对照组(P<0.05),校正TIMI帧数低于对照组(P<0.05);替罗非班组术后LVEF值明显高于对照组,LVEDD、LVESD值明显低于对照组(P<0.05);术前两组PMPs水平比较差异无统计学意义(P>0.05),术后两组PMPs水平均出现显著降低(P<0.05),替罗非班组PMPs水平显著低于对照组(P<0.05)。术后3个月内MACE发生率显著低于对照组(P<0.05),出血并发症发生率比较,差异无统计学意义(P>0.05)。结论在STEMI急诊PCI治疗患者中,替罗非班冠脉内给药可以明显改善术后心肌再灌注和近期心功能,降低外周血内PMPs水平和主要不良心血管事件发生率,并未增加出血事件发生率,临床应用安全有效。
文摘目的:检测血小板减少的急性白血病(AL)患者血小板微颗粒(Platelet microparticle,PMP)、纤维连接蛋白(Fibronectin,FN)、血管性血友病因子(von Willebrand Factor,vWF)的水平,探讨其与出血程度的关系。方法:选择2014年5月至2017年5月初治急性白血病患者101例,依据WHO的出血分级标准,分为0、1、2、3、4,5个不同出血程度亚组;同期选择本院52名正常体检者作为对照。应用流式细胞术和ELISA法分别检测AL组和对照组PMP,FN和vWF的水平,比较2组间PMP,FN和vWF水平差异以及AL组不同出血程度亚组间的差异,分析PMP,FN和vWF的水平与出血的程度之间的关系。结果:初诊急性白血病患者的年龄以18-60岁为主,占61.39%;出血程度以1分为主,占38.61%,AL组患者的PMP,vWF和FN的水平均明显高于对照组(6.06%±4.38%vs 0.89%±0.50%、205.82±24.89 vs 58.04±13.35μg/L、398.29±46.93 vs 311.37±26.02μg/L)(P<0.001)。AL组中PMP,FN和vWF水平在不同出血程度亚组间均不同(P<0.001);PMP和FN水平在0分组最高,4分组最低;vWF水平在4分组最高,0分组最低。急性白血病患者的出血程度与PMP水平呈负相关关系,与FN和vWF水平呈正相关关系(r=-0.753,r=0.648,r=0.805)。结论:检测PMP、FN、vWF水平有助于评估患者出血程度。
基金supported by the National Natural Science Foundation of China(Nos.81473387 and 81503291)the Anhui Province Key Research and Development Program(No.1704a0802141)。
文摘Platelet microparticles(PMPs)are membrane particles derived from the platelet membrane that enter into the blood circulation.We sought to explore the therapeutic effects of Tao-Hong-Si-Wu Decoction(THSWD)on angiogenesis in a rat model of cerebral ischaemia-reperfusion(I/R).The protective effect of THSWD on I/R rats was observed morphologically by immunohistochemical expression of VEGF and CD34,along with immunofluorescence results of co-expression of Brd U and v WF.Then,PMPs from different groups of rats were extracted,and cytokine array analysis was used to screen for angiogenesis associated proteins.The results showed that THSWD can promote the expression of VEGF,CD34,Brd U and v WF.Cytokine array analysis revealed the changes in the expression of 29 related angiogenic proteins in the total protein of PMPs,which involved the Notch signalling pathway.Compared with model group,the expression levels of NICD and Hes-1 in the THSWD group were significantly increased.In the context of I/R,the angiogenesis-related proteins of PMPs are different.THSWD may involve the promotion of activation of the Notch signalling pathway to achieve therapeutic effects on cerebral ischaemia.
